FDA 483 - Mitali Wadekar, M.D. - February 01, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Mitali Wadekar, M.D. in Panorama City, CA, revealed significant deficiencies in the conduct of a human clinical study involving an investigational drug. The clinical investigator failed to adhere to the investigational plan, leading to multiple protocol deviations. These issues included under-dosing of study participants, failure to perform required urine drug screens, improper storage of study drug outside specified temperature ranges, and a missed blood chemistry panel.
ID · 91679020-fc6a-4393-ab88-fadda73c3da4